Arbutus Biopharma Corporation (ABUS) Financial Statements (2024 and earlier)

Company Profile

Business Address 701 VETERANS CIRCLE
WARMINSTER, PA 18974
State of Incorp. BC
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:152,484146,728184,300134,718200,600221,800
Cash and cash equivalents27,19740,57430,77624,00447,32081,330
Short-term investments125,287106,154116,137110,714102,87984,147
Other undisclosed cash, cash equivalents, and short-term investments   37,387 50,40156,323
Receivables2,6142,6641,3521,8351,9701,313
Other undisclosed current assets3,7023,462(34,513)4,583(44,779)(50,415)
Total current assets:158,800152,854151,139141,136157,791172,698
Noncurrent Assets
Operating lease, right-of-use asset1,5851,6651,7441,8211,9222,007
Property, plant and equipment5,3704,8535,0705,2415,4935,664
Long-term investments and receivables11,05731,79037,36355,43650,45056,318
Long-term investments11,05731,79037,36355,43650,45056,318
Other noncurrent assets1162103167180190
Total noncurrent assets:18,02338,37044,28062,66558,04564,179
TOTAL ASSETS:176,823191,224195,419203,801215,836236,877
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:8,8059,65316,02912,26812,4748,715
Accounts payable1,0442,4553,520872 1,194
Accrued liabilities683586518321387621
Other undisclosed accounts payable and accrued liabilities7,0786,61211,99111,07512,0876,900
Deferred revenue15,32715,05516,45614,87816,97323,255
Other undisclosed current liabilities397446372360377439
Total current liabilities:24,52925,15432,85727,50629,82432,409
Noncurrent Liabilities
Long-term debt and lease obligation:    1,9552,0882,100
Liabilities, other than long-term debt8,81412,77115,34516,50716,54921,084
Deferred revenue  3,2965,99910,58510,84215,585
Operating lease, liability1,6461,6711,8151,9552,0882,100
Business combination, contingent consideration, liability7,1687,8047,5315,9225,7075,499
Other undisclosed noncurrent liabilities8,7879,38410,36512,31614,23315,439
Total noncurrent liabilities:17,60122,15525,71030,77832,87038,623
Total liabilities:42,13047,30958,56758,28462,69471,032
Equity
Equity, attributable to parent134,693143,915136,852145,517153,142165,845
Common stock1,344,1951,339,4531,318,7371,307,6541,298,4091,298,212
Additional paid in capital77,20274,23872,40670,73869,13467,151
Accumulated other comprehensive loss(49,468)(49,634)(50,488)(51,004)(50,097)(49,406)
Accumulated deficit(1,237,236)(1,220,142)(1,203,803)(1,181,871)(1,164,304)(1,150,112)
Total equity:134,693143,915136,852145,517153,142165,845
TOTAL LIABILITIES AND EQUITY:176,823191,224195,419203,801215,836236,877

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues4,6516,6876,2455,95214,24112,581
Premiums earned, net  4,100   4,100
Gross profit:4,6516,6876,2455,95214,24112,581
Operating expenses(23,036)(24,100)(28,807)(23,763)(28,350)(23,555)
Operating loss:(18,385)(17,413)(22,562)(17,811)(14,109)(10,974)
Nonoperating income (expense)1,2911,074630244(83)(347)
Investment income, nonoperating1,4611,268943694396159
Interest and debt expense(171)(198)(309)(429)(482)(506)
Loss from continuing operations before equity method investments, income taxes:(17,265)(16,537)(22,241)(17,996)(14,674)(11,827)
Other undisclosed income (loss) from continuing operations before income taxes171198(1,417)429482506
Loss from continuing operations before income taxes:(17,094)(16,339)(23,658)(17,567)(14,192)(11,321)
Income tax expense      (4,444)
Loss from continuing operations:(17,094)(16,339)(23,658)(17,567)(14,192)(15,765)
Loss before gain (loss) on sale of properties:(17,567)(14,192)(15,765)
Net loss:(17,094)(16,339)(23,658)(17,567)(14,192)(15,765)
Other undisclosed net income attributable to parent   1,726   
Net loss available to common stockholders, diluted:(17,094)(16,339)(21,932)(17,567)(14,192)(15,765)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net loss:(17,094)(16,339)(23,658)(17,567)(14,192)(15,765)
Other comprehensive loss    (907)(691)(1,071)
Other undisclosed comprehensive loss   (2,153)   
Comprehensive loss:(17,094)(16,339)(25,811)(18,474)(14,883)(16,836)
Other undisclosed comprehensive income, net of tax, attributable to parent1668544,395   
Comprehensive loss, net of tax, attributable to parent:(16,928)(15,485)(21,416)(18,474)(14,883)(16,836)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: